Bibliographic Details
| Title: |
IKZF1 in acute lymphoblastic leukemia: the rise before the fall? |
| Authors: |
Østergaard, Anna, Boer, Judith M., van Leeuwen, Frank N., Pieters, Rob, Den Boer, Monique L. |
| Source: |
Leukemia & Lymphoma; Dec2024, Vol. 65 Issue 14, p2077-2087, 11p |
| Subject Terms: |
LYMPHOBLASTIC leukemia, TRANSCRIPTION factors, ACUTE leukemia, SUBSTANCE abuse relapse, CELL communication |
| Abstract: |
Acute lymphoblastic leukemia (ALL) is the most common malignancy in children and adolescents and in recent decades, the survival rates have risen to >90% in children largely due the introduction of risk adapted therapy. Therefore, knowledge of factors influencing risk of relapse is important. The transcription factor IKAROS is a regulator of lymphocyte development and alterations of its coding gene, IKZF1, are frequent in ALL and are associated with higher relapse risk. This concise review will discuss the normal function of IKAROS together with the effect of gene alterations in ALL such as relieved energy restriction and altered response to anti-leukemic drugs. Besides the biology, the clinical impact of gene alterations in the different subtypes of ALL will be discussed. Finally, possibilities for treating ALL with IKZF1 alterations will be considered including novel therapies like cell signaling inhibitors and immunotherapy. [ABSTRACT FROM AUTHOR] |
|
Copyright of Leukemia & Lymphoma is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
|
Full text is not displayed to guests. |
Login for full access.
|
